Nabriva Therapeutics plc

Nabriva Therapeutics plc

OOTC:NBRVF
0.00
USD
+0.00
(-66.67%)
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

CEO
H. Michael Hogan
Full Time Employees
39
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Alexandra House Dublin DU Ireland 4
IPO Date
Sep 18, 2015
Business
Nabriva Therapeutics plc is a biopharmaceutical company specializing in the development and commercialization of anti-infective agents for the treatment of serious infections. Its core product portfolio includes novel antibiotics such as lefamulin, marketed under the brand name Xenleta, which is approved for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. The company focuses on innovative therapeutic solutions addressing multidrug-resistant bacterial pathogens. Nabriva operates primarily in North America and Europe, targeting healthcare providers and medical institutions. Founded in 2006, the company is headquartered in Dublin, Ireland, and has development and commercialization activities in various international markets. Nabriva pursues strategic partnerships and collaborations to expand its product pipeline and market reach. In recent major developments, Nabriva has advanced its clinical pipeline with new product formulations and delivery methods, and it has entered into strategic collaborations to enhance commercialization and distribution efforts. The company has strengthened its position through business expansions aimed at addressing urgent medical needs related to antimicrobial resistance. These strategic moves illustrate Nabriva's commitment to innovation and growth within the pharmaceutical industry.